Kaposi Sarcoma

Biopsy a representative, non-necrotic cutaneous, oral, nodal, or visceral lesion when Kaposi sarcoma (KS) is suspected. Histology with immunohistochemistry is the diagnostic standard, and nuclear HHV-8 latent nuclear antigen-1 (LANA-1) positivity supports KS in the appropriate morphologic setting. ScienceDirect+2ScienceDirectDiagnosis and treatment of Kaposi's sarcoma: European consensus-based interdisciplinary guideline (EDF/EADO/EORTC)PubMedEvaluation of Clinical and Histopathological Diagnosis of Kaposi’s Sarcoma at Muhimbili National Hospital, Dar es Salaam, Tanzania - PMCPubMedImmunohistochemical detection of the latent nuclear antigen-1 of the human herpesvirus type 8 to differentiate cutaneous epidemic Kaposi sarcoma and its histological simulators - PMC

Request HHV-8 LANA-1 immunohistochemistry explicitly when morphology is subtle, when a lesion is ulcerated or secondarily infected, or when the specimen is a small biopsy. Early KS can be histologically obscured and overlap with inflammatory conditions, especially stasis dermatitis; LANA-1 staining distinguished KS from histologic simulators in one study. PubMedPubMedImmunohistochemical detection of the latent nuclear antigen-1 of the human herpesvirus type 8 to differentiate cutaneous epidemic Kaposi sarcoma and its histological simulators - PMC

A negative or equivocal small biopsy should not automatically end the workup when clinical suspicion remains high. Obtain a deeper or more representative lesional specimen and involve dermatopathology, because ulceration, lymphedema, inflammation, and infection can distort typical histologic architecture. PubMedPubMedImmunohistochemical detection of the latent nuclear antigen-1 of the human herpesvirus type 8 to differentiate cutaneous epidemic Kaposi sarcoma and its histological simulators - PMC

At diagnosis, obtain HIV serology in every patient with KS and review prior HIV testing, antiretroviral therapy exposure, HIV RNA suppression, and CD4 count when HIV is present. KS is categorized clinically as classic, endemic, iatrogenic/immunosuppression-associated, or epidemic/AIDS-associated; a fifth HIV-negative men-who-have-sex-with-men phenotype has also been described. Wiley+3WileyTopical treatments for Kaposi sarcoma: A systematic reviewScienceDirectPathophysiology, diagnosis, and emerging treatments for Kaposi sarcoma: A clinical reviewScienceDirectDiagnosis and treatment of Kaposi's sarcoma: European consensus-based interdisciplinary guideline (EDF/EADO/EORTC)PubMedCurrent and Future Tools for Diagnosis of Kaposi’s Sarcoma - PMC

Identify iatrogenic KS by documenting transplant status and current or prior long-term immunosuppressive therapy. This distinction is immediately actionable because reduction or withdrawal of immunosuppression is the initial disease-directed intervention, balanced against risk of graft rejection or flare of the underlying inflammatory disease. Wiley+1WileyClinical update on cutaneous and subcutaneous sarcomasScienceDirectDiagnosis and treatment of Kaposi's sarcoma: European consensus-based interdisciplinary guideline (EDF/EADO/EORTC)

Document disease distribution at baseline: total cutaneous burden, lesion sites, edema, ulceration, pain, bleeding, functional compromise, oral involvement, lymphadenopathy, and symptoms suggesting gastrointestinal or pulmonary disease. Classic KS most often follows a chronic, generally indolent course on the extremities of older patients, whereas epidemic and iatrogenic forms more often have severe cutaneous, nodal, mucosal, or visceral involvement. ScienceDirect+1ScienceDirectDiagnosis and treatment of Kaposi's sarcoma: European consensus-based interdisciplinary guideline (EDF/EADO/EORTC)ScienceDirectKaposi Sarcoma and Cutaneous Angiosarcoma: Guidelines for Diagnosis and Treatment

Use laboratory testing and imaging selectively to establish clinically relevant burden. Clinical examination, HIV serology, routine blood testing, and histology are core assessments; CD4 count is mandatory in AIDS-associated KS and useful in iatrogenic KS. Total-body CT is generally used for AIDS-associated and iatrogenic KS, while bronchoscopy and upper endoscopy are symptom-directed. PubMedPubMedCurrent and Future Tools for Diagnosis of Kaposi’s Sarcoma - PMC

Use local therapy for localized lesions that are symptomatic, cosmetically distressing, bleeding, painful, or functionally consequential. Radiotherapy, intralesional chemotherapy, and electrochemotherapy have high response rates; cryotherapy, laser ablation, excision, topical imiquimod, and topical 9-cis-retinoic acid are additional local options. Local treatments control treated lesions but do not address multifocal or visceral disease. ScienceDirect+2ScienceDirectPathophysiology, diagnosis, and emerging treatments for Kaposi sarcoma: A clinical reviewWolters KluwerS1877 Rectal Kaposi Sarcoma in an Immunocompetent PatientScienceDirectDiagnosis and treatment of Kaposi's sarcoma: European consensus-based interdisciplinary guideline (EDF/EADO/EORTC)

Escalate to systemic treatment for locally aggressive, extensive, or disseminated KS, including clinically important visceral involvement. Pegylated liposomal doxorubicin (PLD) and paclitaxel are recommended first-line systemic agents in the European interdisciplinary consensus guideline. The supplied evidence supports agent selection but does not establish a regimen-specific dose, interval, organ-adjustment protocol, or laboratory monitoring schedule; follow current product labeling and oncology protocols for those details. ScienceDirectScienceDirectDiagnosis and treatment of Kaposi's sarcoma: European consensus-based interdisciplinary guideline (EDF/EADO/EORTC)

Pomalidomide is approved for disseminated KS across clinical subtypes and may be useful when cytotoxic chemotherapy is poorly tolerated. Its role relative to PLD or paclitaxel should be individualized because comparative controlled evidence for newer strategies remains limited. ScienceDirectScienceDirectPathophysiology, diagnosis, and emerging treatments for Kaposi sarcoma: A clinical review

For classic KS in younger patients requiring systemic treatment, PLD or low-dose interferon-alfa are recommended first-line options in the consensus guideline. Use the clinical tempo and extent—not lesion count alone—to decide whether repeated local procedures remain reasonable versus systemic treatment. ScienceDirectScienceDirectDiagnosis and treatment of Kaposi's sarcoma: European consensus-based interdisciplinary guideline (EDF/EADO/EORTC)

For AIDS-related KS, combination antiretroviral therapy (ART) is the initial treatment option and can produce KS responses without immediate chemotherapy in some patients. ART should not delay KS-directed systemic treatment when disease is extensive, rapidly consequential, or requires treatment in the setting of immune reconstitution inflammatory syndrome. ScienceDirect+2ScienceDirectDiagnosis and treatment of Kaposi's sarcoma: European consensus-based interdisciplinary guideline (EDF/EADO/EORTC)Oxford AcademicAs-Needed Vs Immediate Etoposide Chemotherapy in Combination ...Oxford AcademicAcquired Immunodeficiency Syndrome-Related Kaposi's Sarcoma ...

After ART initiation or optimization, reassess cutaneous, mucosal, nodal, and visceral disease clinically. Progression despite improving HIV control, or disease that is extensive at presentation, should prompt systemic KS therapy rather than repeated changes to local treatment alone. ScienceDirect+1ScienceDirectDiagnosis and treatment of Kaposi's sarcoma: European consensus-based interdisciplinary guideline (EDF/EADO/EORTC)Oxford AcademicAs-Needed Vs Immediate Etoposide Chemotherapy in Combination ...

For iatrogenic KS, discuss a planned taper, withdrawal, or modification of immunosuppressive therapy with transplant or disease-specific specialists before assuming chemotherapy is necessary. The expected antitumor benefit must be balanced against allograft loss, rejection, or recurrence of the underlying disease; persistent, extensive, or disseminated KS still warrants local or systemic therapy based on burden. Wiley+1WileyClinical update on cutaneous and subcutaneous sarcomasScienceDirectDiagnosis and treatment of Kaposi's sarcoma: European consensus-based interdisciplinary guideline (EDF/EADO/EORTC)

At each follow-up, compare lesion number and distribution, lesion-associated pain or bleeding, edema, oral involvement, lymphadenopathy, and functional limitation against baseline documentation. Reassess the treatment strategy when disease becomes locally aggressive, extensive, or disseminated, because these are the consensus indications for systemic therapy. ScienceDirectScienceDirectDiagnosis and treatment of Kaposi's sarcoma: European consensus-based interdisciplinary guideline (EDF/EADO/EORTC)

New gastrointestinal symptoms should prompt endoscopic evaluation with biopsy, and respiratory symptoms should prompt chest evaluation with consideration of bronchoscopy. Gastrointestinal KS may lack classic endoscopic appearance and can precede cutaneous diagnosis; direct tissue evaluation avoids misattributing symptoms to HIV or other immunosuppression-related conditions. PubMed+1PubMedDiagnosis of Kaposi’s sarcoma via gastric biopsy leading to the detection of an AIDS case in a report - PMCPubMedCurrent and Future Tools for Diagnosis of Kaposi’s Sarcoma - PMC

HHV-8 nucleic acid testing in blood or other specimens may assist monitoring in selected cases, and higher viral burden has correlated with tumor burden in AIDS-associated KS. It should complement, not replace, serial clinical examination and histologic confirmation when diagnostic uncertainty persists. PubMedPubMedCurrent and Future Tools for Diagnosis of Kaposi’s Sarcoma - PMC